Role of 5FU and Xeloda in pancreatic cancer progressing after gemcitabine – pro
5 florouracyl is an older drug but it has some response in pancreatic cancer, as does its analogue, Xeloda. The role of Xeloda alone to salvage pancreatic cancer patients who progress on gemcitabine. Technically Xeldda is first line in this case, because gemcitabine was stopped due to intolerance rather than progression; however, restaging after gemcitabine was not provided.
The role of Xeloda alone for adjuvant therapy of pancreatic cancer can be supported but only thorugh the analogy of the similarity between 5FU and Xeloda, as specific trials in the adjuvant setting are lacking. patients who progress on gemcitabine. NCCN does list Xeloda as a 2B recommendation for the adjuvant setting. This means that based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate
Lutz MP, Ducreux M, Wagener T, et al, Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group. Proceedings of the American Society of Clinical Oncology 2002;21:125a, abstract 498
Scheithauer W, Schüll B, Ulrich-Pur H, et al, Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma. Proceedings of the American Society of Clinical Oncology;21:126a, abstract number 500
nccn.org, pancreatic, PANC-G, 2012
David B. Smith, John P. Neoptolemos, Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas 2010, http://www.dovepress.com/capecitabine-an-evidence-based-review-of-its-effectiveness-in-the-trea-peer-reviewed-article-CE-recommendation1
V. Heinemann, R. Labianca, A. Hinke, and C. Louvet Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study Ann. Onc., October 1, 2007; 18(10): 1652 – 1659.
D. H. Palmer, D. D. Stocken, H. Hewitt, C. E. Markham, A. B. Hassan, P. J. Johnson, J. A. C. Buckels, and S. R. Bramhall
A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin
Ann. Surg. Oncol., July 1, 2007; 14(7): 2088 – 2096.